Back to top
more

Intellia Therapeutics (NTLA)

(Real Time Quote from BATS)

$24.84 USD

24.84
258,570

-0.04 (-0.16%)

Updated May 24, 2024 02:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NTLA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Intellia Therapeutics, Inc. [NTLA]

Reports for Purchase

Showing records 261 - 278 ( 278 total )

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 261

11/01/2017

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 262

09/27/2017

Company Report

Pages: 8

Updated Mouse Data Shows Long-Term Benefit with Crispr/ Cas9

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 263

08/01/2017

Company Report

Pages: 7

2Q,Achieves Key Preclinical Milestones

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 264

05/19/2017

Industry Report

Pages: 6

EHA Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 265

05/15/2017

Daily Note

Pages: 5

ASGCT Presentations Show TTR Editing Success in Second Animal Model, We Expect Studies in Non-Human Primates to Start Later this Year, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 266

05/03/2017

Company Report

Pages: 6

Recent Presentations Highlight Gene Editing Success in Mouse Models, Studies in Non-Human Primates to Begin Later this Year

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 267

03/17/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 268

03/14/2017

Company Report

Pages: 6

4Q/FY16, We Look for Additional Tech Improvements and Preclinical Progress in 2017, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 269

02/16/2017

Company Report

Pages: 7

Patent Interference Ruling Surprising, Expecting Appeals Ahead, Reiterate OP but Cutting PT to $25 on IP Overhang

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 270

02/10/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 271

01/30/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 272

01/13/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 273

11/01/2016

Company Report

Pages: 6

3Q, We See Valuation Disconnect in NTLA, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 274

10/21/2016

Daily Note

Pages: 5

Undervalued Relative to Peers, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 275

08/22/2016

Daily Note

Pages: 5

Additional Preclinical Data from TTR Program Presented, Supports LNP Delivery Strategy, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 276

08/05/2016

Company Report

Pages: 7

2Q, Well Capitalized to Advance Crispr/Cas9 Technology Forward, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 277

06/23/2016

Company Report

Pages: 7

Positive Readthrough from Unanimous RAC Support for First-in-Human Academic Crispr Study, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Unclassified

Record: 278

05/31/2016

Company Report

Pages: 32

Initiating Coverage with an OUTPERFORM Rating and $38 Price Target, The Genius of Gene Editing

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party